Dr. Drew Moghanaki joins LUNGevity Foundation Scientific Advisory Board

Dr. Moghanaki, Radiation Oncologist and Director of Clinical Radiation Oncology Research, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia, brings expertise in radiation oncology and other key areas to LUNGevity’s research program
Media Contact: 

Linda Wenger

Dr. Drew Moghanaki
Dr. Drew Moghanaki

WASHINGTON, DC (August 17, 2017) – LUNGevity Foundation is proud to announce that Drew Moghanaki, MD, MPH, has joined its distinguished Scientific Advisory Board.

Dr. Moghanaki is a highly regarded expert in the field of radiation oncology and leads the Clinical Radiation Oncology Research program at Hunter Holmes McGuire Veterans Affairs Medical Center in Richmond, Virginia. Dr. Moghanaki has been instrumental in bringing more than $34 million in funding to improve outcomes for lung cancer patients through a phase III lung cancer trial for veterans and a key VA partnership to increase access to lung cancer screening.

LUNGevity’s Scientific Advisory Board oversees the Foundation’s scientific strategy and ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of all people diagnosed with lung cancer. LUNGevity’s awardees are working to improve our ability to detect, diagnose, and treat lung cancer, as well as prevent its recurrence. LUNGevity is the only lung cancer non-profit with a long-term, strategic focus on the early detection of lung cancer.

“We are thrilled to have Dr. Moghanaki join LUNGevity’s Scientific Advisory Board,” said Andrea Ferris, president of LUNGevity Foundation. “He brings expertise in radiation oncology as well as a deep knowledge of the VA healthcare system. We are excited to have his unique perspective and expertise to help guide our research program.” 

For interviews with LUNGevity President Andrea Ferris, please contact Linda Wenger at (973) 449-3214 or lwenger@LUNGevity.org.

About LUNGevity Foundation

LUNGevity is the nation's leading lung cancer organization investing in lifesaving, translational research and providing support services and education for patients and caregivers. LUNGevity’s goals are three-fold: (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.

LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. LUNGevity’s comprehensive resources include a medically vetted website, a toll-free HELPLine in partnership with CancerCare®, a unique Lung Cancer Navigator app, peer-to-peer mentoring for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our Clinical Trial Finder tool, a Clinical Trial Ambassador program, and participation with EmergingMed.

Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.

About Lung Cancer in the U.S.

  • About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime
  • More than 222,000 people in the U.S. will be diagnosed with lung cancer this year
  • About 60%-65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers
  • Lung cancer takes more lives than the next three leading cancers (colorectal, breast, and prostate) combined
  • Only 18% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it’s caught before it spreads, the chance of 5-year survival improves dramatically